106 Results (Page 1 of 9)
China Markets Research Reports
China Diabetes Devices Market Analysis
The China Diabetes Devices Market is expected to grow from $1.82 Bn in 2022 to $3.56 Bn in 2030 with a CAGR of 8.70% for the forecasted year 2022-2030. Diabetes is a common condition in China, where the demand for diabetes-related products and devices is rising. The prevalence of diabetes is anticipated to increase as the population ages and urbanizes, providing significant opportunities for diabetes device manufacturers. The market is segmented by type and by the end user. Some key players in this market include Lepu Medical Technology, MicroPort, Johnson & Johnson, Medtronic, Roche, Ascensia Diabetes Care and Dexcom.
China Cardiac Surgery Instruments Market Analysis
The China Cardiac Surgery Instruments Market is expected to witness growth from $166 Mn in 2022 to $310 Mn in 2030 with a CAGR of 8.10% for the forecasted year 2022-2030. In China, due to rising disposable income, more people in China can now access better healthcare services like cardiac surgeries. This has increased demand for cardiac surgery equipment, providing manufacturers with new business opportunities. The market is segmented by type, application and by end user. Some key players in this market include Lepu Medical Technology, MicroPort, LivaNova, B. Braun, Medline Industries, KLS Martin, and STILLE.
China Cardiovascular Diseases Therapeutics Market Analysis
China's cardiovascular disease therapeutics market is expected to witness growth from $13.07 Bn in 2022 to $25.52 Bn in 2030 with a CAGR of 8.72% for the year 2022-30. The shifting lifestyle modifications in China have led to an increase in the prevalence of cardiovascular diseases, therefore, driving the growth of the market. The China cardiovascular disease therapeutics market is segmented by disease indication, drug type, route of administration, drug classification, mode of purchase, and by the end user. Lanrui Boyan Medical, Beijing Handian Pharmacy, and AstraZeneca are the major players in the China cardiovascular disease therapeutics market.
China Anti Aging Therapeutics Market Analysis
China anti-aging therapeutics market is projected to grow from $49 Mn in 2022 to $183 Mn in 2030 with a CAGR of 18.03% for the year 2022-2030. As China has the fastest-growing elderly population in the world, the market is projected to expand during the forecast period. Further, the concerns over the appearance on social media among the young Chinese population are also responsible for the growth of the market. The China anti-aging therapeutics market is segmented by product, treatment, target group, type of aging, type of molecules, mechanism of action, ingredient, and by distribution channel. Some of the top players in the market include Harbour BioMed, Hua Medicine, and Rejuvenate Bio.
China Healthcare Insurance Market Analysis
The China healthcare insurance market is projected to grow from $162.88 Bn in 2022 to $326.94 Bn by 2030, registering a CAGR of 9.1% during the forecast period of 2022 - 2030. The main factors driving the growth would be increasing health insurance premiums, growing awareness of health risks and rising medical costs. The market is segmented by component, the provider, coverage, health insurance plans and end-user. Some major players include Ping and Insurance, China Life Insurance, People’s Insurance, China Pacific Insurance and New China Life Insurance.
China Artificial Intelligence (AI) in Healthcare Market Analysis
China's Artificial Intelligence (AI) in the healthcare market is projected to grow from $0.55 Bn in 2022 to $11.91 Bn by 2030, registering a CAGR of 46.72% during the forecast period of 2022-30. The market will be driven by rising demand for healthcare services & a robust startup and innovation ecosystem. The market is segmented by healthcare components & by healthcare applications. Some of the major players include Google Health, Tencent Trusted Doctors & NERVTEX.
China Healthcare Claims Management Market Analysis
The China healthcare claims management market is projected to grow from $2.15 Bn in 2022 to $12.71 Bn by 2030, registering a CAGR of 24.9% during the forecast period of 2022 - 2030. The main factors driving the growth would be the growing adoption of digital healthcare, increasing healthcare fraud, government initiatives and increasing healthcare spending. The market is segmented by component, type, delivery mode and by end-user. Some of the major players include Ping a Healthcare, China Pacific Insurance, Cognizant, Allianz and Cigna.
China Diagnostic Imaging Services Market
The China Diagnostic Imaging Services market size was valued at $42 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 4.9 % from 2022 to 2030 and will reach $61.58 Bn in 2030. The market is segmented by product, application, and end user. The China Diagnostic Imaging Services market will grow as the development of new 3D printing materials and techniques has led to the production of more complex and customizable medical devices. The key market players are Canon Medical Systems Corporation, Carestream Health Inc., Esaote SpA, FUJIFILM Holdings Corporation, and GE Healthcare.
China ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis
China's Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market is projected to grow from $2.37 Bn in 2022 to $4.73 Bn in 2030 with a CAGR of 9% for the year 2022-30. A more significant proportion of the young population and therefore an increasing prevalence of ADHD among children in China are driving the growth of the market. The China ADHD therapeutics market is segmented by drug, drug type, demographics, and by distribution channel. Shanghai Fosun Pharmaceutical, Huadong Medicine, and Adlon Therapeutics are the key players in the market.
China Oncology Clinical Trials Market Analysis
China's oncology clinical trials market is projected to grow from $1.02 Bn in 2022 to $1.75 Bn by 2030, registering a CAGR of 7% during the forecast period of 2022-30. The market will be driven by the rising incidence of cancer in the country and efforts to promote research, collaboration, and innovation. The market is segmented by phase, by study design & by indication. Some of the major players include Novartis AG, Roche Holding AG, Jiangsu Hengrui Pharmaceutical & Sino Biopharmaceutical.
China Oral Care Market Analysis
The China Oral Care market was valued at $2.8 Bn in 2022 and is estimated to expand at a CAGR of 7.7% from 2022 to 2030 and will reach $5.1 Bn in 2030. One of the main reasons propelling the growth of this market is introduction of newer technologies, aging population. The market is segmented by type, drug and distribution channel. Some key players in this market are Hawley & Hazel, Yunnan Baiyao Group, Shanghai Jahwa United Co, Guangzhou Lion Company, Fujian Sanli Group, Midmark, iByer Dental Group, Bybo Dental Group, ChengDu Huamei Dental Chain Co, Sirona Dental Systems, Foshan among others.
China Liver Diseases Therapeutics Market Analysis
By 2030, it is anticipated that the China Liver Disease Therapeutics market will reach a value of $3.23 Bn from $1.85 Bn in 2022, growing at a CAGR of 7.2% during 2022-2030. Liver Disease Therapeutics in China is dominated by a few domestic pharmaceutical companies such as Simcere, Beijing, and Fosun Pharma. The Liver Disease Therapeutics market in China is segmented into different types of disease and different therapy types. Some of the major factors affecting the China Liver Disease Therapeutics market are the growing prevalence of liver diseases and unhealthy and dynamic lifestyles.
China Multiple Myeloma Therapeutics Market Analysis
The China Multiple Myeloma Therapeutics Market was valued at $670 Mn in 2022 and is estimated to expand at a CAGR of 7.5% from 2022 to 2030 and will reach $1069 Mn in 2030. One of the main reasons propelling the growth of this Market is Rising disposable income, aging population. The Market is segmented by type, drug and distribution channel. Some key players in this Market are BeiGene, Innovent Biologics, Simcere, Hengrui Medicine, CSPC Pharmaceutical and others.
China Diabetes Drugs Market Analysis
The China diabetes drugs market size was valued at $4.96 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 7.6% from 2022 to 2030 and will reach $8.9 Bn in 2030. The market is segmented by drug type, application, and distribution channel. The China diabetes drug market will grow because China is the country with the largest population of people with diabetes in the world. The key market players are Gan & Lee Pharmaceuticals (CHN), Tonghua Dongbao Pharmaceutical (CHN), Jiangsu Hengrui Medicine (CHN), and others.
China Alexipharmic Drugs Market Analysis
China's Alexipharmic drugs market size was valued at $xx Bn in 2022 and is estimated to expand at a CAGR of 6.20% from 2022-30 and will reach $xx Bn in 2030. The market is segmented by product type, indication, route of administration, end-user, and distribution channel. The China Alexipharmic Drugs market will grow because the Chinese government and healthcare providers are increasing their efforts to raise public awareness about poisoning and the availability of antidotes. The key market players are Beijing Kawin Technology Share-Holding (CHN), Yino Pharma Limited (CHN), and others.
China Connected Healthcare Market Analysis
The China-connected healthcare market is projected to grow from $5.34 Bn in 2022 to $43.25 Bn by 2030, registering a CAGR of 29.9% during the forecast period of 2022 - 2030. The main factors driving the growth would be a large and ageing population, government support, technological advancements and a rising middle class. The market is segmented by type, function and by application. Some of the major players include Tencent Health, JD Health International, WeDoctor, iCarbonX, Roche, GE Healthcare and Medtronic.
China Primary Hyperoxaluria (PH) Therapeutics Market Analysis
The China Primary Hyperoxaluria (PH) Therapeutics Market was valued at $XX Bn in 2022 and is estimated to expand at a CAGR of 6.3% from 2022 to 2030 and will reach $XX B in 2030. One of the main reasons propelling the growth of this market is, advancement of medication. The market is segmented by diagnostic method, by treatment, by type. Some key players in this market are Arbor Pharmaceuticals, Alnylam Pharmaceuticals, Dicerna Pharmaceuticals, OxThera, Retrophin Pharma, Pharming Group among others.
China Neurology Clinical Trials Market Analysis
The China Neurology Clinical Trials market is projected to grow from $420.4 Mn in 2022 to $722.4 Mn by 2030, registering a CAGR of 7% during the forecast period of 2022 - 2030. The market will be driven by the country's increasing incidence of neurological disorders and pharmaceutical firms boosting their investments in R&D. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer, Novartis, Shanghai Green Valley Pharmaceuticals & Jiangsu Hengrui Medicine.
China 3D Printing Medical Devices Market Analysis
The China 3D Printing Medical Devices market size was valued at $239 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 17.8% from 2022 to 2030 and will reach $ 885 Mn in 2030. The market is segmented by component, application, technology, and end user. The China 3D Printing Medical Devices market will grow as the 3D printing technology allows for the customization of medical devices, which is becoming increasingly important in the healthcare industry. The key market players are Tiertime, Beijing Long Yuan Automated Fabrication System Co., Ltd., Shining 3D and others.
China Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market Analysis
The China COPD Therapeutics Market was valued at $1.46 Bn in 2022 and is estimated to expand at a CAGR of 8.6% from 2022 to 2030 and will reach $2.84 Bn in 2030. One of the main reasons propelling the growth of this market is increase prevalence rate, air pollution and smoking. The market is segmented by Drug class and By distribution channel. Some key players in this market are SinoPharm Group, Hutchison China MediTech, Zhejiang Hisun Pharmaceutical, Haisco Pharmaceutical Group, Shanghai Sine Promod Pharmaceutical, Astellas Pharma, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Novartis, Pfizer, Teva China Limited and others.
China Teleradiology Market Analysis
The China Teleradiology market size was valued at $191 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 12.20% from 2022 to 2030 and will reach $ 514 Mn in 2030. The market is segmented by application, modality, technology solutions, and end user. The China teleradiology market will grow due to Increasing demand for remote radiology services. The key market players are United Imaging Healthcare (UIH), AliHealth, Nanjing Remote Medical Imaging (NRMI), Beijing Deepwise & League of PHD Technology (DL), Yitu Healthcare, and others.
China Alzheimer’s Disease Drugs Market Analysis
The China Alzheimer’s Disease Drugs market was valued at $1.24 Bn in 2022 and is estimated to expand at a CAGR of 9.42% from 2022-30 and will reach $2.64 Bn in 2030. One of the main reasons propelling the growth of this market is government support, and the aging population. The market is segmented by drug classes and by Distribution Channels. Some key players in this market are Shanghai Green Valley Pharmaceutica, Eisai Co., Eli Lilly and Company, H. Lundbeck A/S, Johnson and Johnson, Hengrui Medicine Co, Jiangsu Hengrui, Novartis AG, Chongqing Zhifei Biological Products, Pfizer and CSPC Pharmaceutical Group among others.
China Infectious Disease Therapeutics Market Analysis
By 2030, it is anticipated that the China infectious disease therapeutics market will reach a value of $15.19 Bn from $9.64 Bn in 2022, growing at a CAGR of 5.9% during 2022-2030. Infectious Disease Therapeutics in China is dominated by a few domestic pharmaceutical companies such as WuXi Biologics, Fosun Pharma and CanSino Biologics. The infectious disease therapeutics market in China is segmented into different therapeutic areas and different treatment types. The major factors affecting the China infectious disease therapeutics market are the increasing disease burden of communicable diseases like TB, hepatitis, and COVID-19 and the amount of healthcare funding for infectious diseases treatment in various areas of China.
China Clinical Diagnostics Market Analysis
China's clinical diagnostic market was valued at $5.5 Bn in 2022 and is estimated to expand at a CAGR of 7.5% from 2022-30 and will reach $9.9 Bn in 2030. One of the main reasons propelling the growth of this market is an increase in chronic disease and the aging population. The market is segmented by type, drug, and distribution channel. Some key players in this market are Abbott, BD, bioMérieux SA, Bio-Rad Laboratories, Danaher Corporation, Siemens AG, Hologic, Qiagen NV, Quest Diagnostics, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, Sysmex, Mindray, Shanghai Fosun Pharmaceutical Group, Guangzhou Wondfo Biotech, Beijing Leadman Biochemistry Co. and others.
China Patient Engagement Solutions Market Analysis
The China patient engagement solutions market is projected to grow from $1.37 Bn in 2022 to $3.82 Bn by 2030, registering a CAGR of 13.7% during the forecast period of 2022 - 2030. The main factors driving the growth would be the ageing population, chronic disease management, increasing healthcare spending and government support. The market is segmented by component, delivery mode, application, therapeutic area, functionality and end-user. Some major players include JD Health, Vecoton, Ping An Good Doctor, Oracle and Lincor.